Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Amphivena Therapeutics logo — Empowering Cancer Patients with Dual-Action Immuno-Oncology...

Amphivena Therapeutics

Empowering Cancer Patients with Dual-Action Immuno-Oncology Biologics

Founded 2012 Series C Total: $135.69M Biotechnology, Health Care +1

General Information

Company Name Amphivena Therapeutics
Founded Year 2012
Founders / Decision Makers
Team member Team member Team member
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series C
Social

Get notified when Amphivena Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Amphivena Therapeutics

Amphivena Therapeutics is a biotechnology startup established in 2012 and headquartered in South San Francisco, California. The company's focus is on immuno-oncology, aiming to empower cancer patients with dual-action biologics through its ReSTORE platform. This platform is designed to combat immune suppression and stimulate T cell effector function in cancer patients. By incorporating elements of avidity, target selectivity, and enhanced safety within a single molecule, Amphivena Therapeutics can engineer the biologics to include additional features for solid tumor targeting and direct tumor cell elimination. In September 2019, Amphivena Therapeutics secured a significant $62.00M Series C investment. The funding was provided by a group of prominent investors including MPM Capital, Qiming Venture Partners, Aju IB Investment, Clough Capital, Franklin Berger, Mérieux Equity Partners, ND Capital, Solasta Ventures, Industrial Investors Group, and Newton Investment Management. This investment signifies confidence in the potential of Amphivena Therapeutics and its innovative approach to immuno-oncology, positioning the startup for continued growth and impact in the healthcare and biotechnology industries.

Taxonomy: Amphivena Therapeutics, Cancer Treatment, Immuno-Oncology, Biologics, Clinical-stage, ReSTORE Platform, Dual-Action Biologics, Tumor Targeting, Avidity, T Cell Activation, Immune Suppression, Solid Tumor Therapy, South San Francisco, California, Healthcare Innovation

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• 10
Investor Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		24 Sep 2019
Venture Round •••••• - 10 Dec 2018
Series B •••••• - 26 Jul 2017
Venture Round •••••• - 04 May 2015
Series A •••••• - 15 Jul 2013

Amphivena Therapeutics Alternatives & Competitors

Amphivena Therapeutics vs
Bicara Therapeutics
Bicara Therapeutics United States

Pioneering bifunctional antibodies for targeted tumor modulation

IPO
123 employees
Biopharma, Biotechnology
Amphivena Therapeutics vs
Thunder Biotech
Thunder Biotech United States

MOTO-CAR®s: Innovative macrophage technology designed to provide effective treatment for patients wi...

Debt Financing
15 employees
Biotechnology, Pharmaceutical
Amphivena Therapeutics vs
BioVaxys Technology Corp.
BioVaxys Technology Corp. Canada

Antiviral and Anticancer Vaccine Platforms Harnessing the Power of T-Cells

Post Ipo Equity
5 employees
Biopharma, Biotechnology

FAQ About Amphivena Therapeutics

Empowering Cancer Patients with Dual-Action Immuno-Oncology Biologics
Amphivena Therapeutics was founded in 2012.
Amphivena Therapeutics operates in the following industries: Biotechnology, Health Care, Health and Wellness.
Amphivena Therapeutics has completed 5 funding rounds, raising a total of $135.69M. The latest funding stage is Series C.
Top alternatives and competitors to Amphivena Therapeutics include Bicara Therapeutics, Thunder Biotech, BioVaxys Technology Corp., Huasaiboman Medical Cell Biology, TATUM bioscience. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Amphivena Therapeutics and Bicara Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Amphivena Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy